AstraZeneca Hits Sandoz With Seroquel Patent Suit
The suit was filed Friday in New Jersey on behalf of AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited against Sandoz Inc.
The suit centers on U.S. Patent Number 4,879,288—entitled “novel dibenzothiazepine antipsychotic” and owned by AstraZeneca. The ‘288 patent covers quetiapine fumarate, the active ingredient in Seroquel.
The ‘288 patent had been slated to expire...
To view the full article, register now.